18:38 , Aug 10, 2018 |  BC Week In Review  |  Clinical News

Second Vertex drug caught in CF standoff

NICE's suspension of its review of Symkevi tezacaftor/ivacaftor on Aug. 9 marks the latest delay of access in England and Wales to cystic fibrosis drugs from Vertex Pharmaceuticals Inc. (NASDAQ:VRTX). NICE suspended its review after the...
21:23 , Aug 9, 2018 |  BC Extra  |  Company News

Second Vertex drug caught in CF standoff

NICE's suspension of its review of Symkevi tezacaftor/ivacaftor on Thursday marks the latest delay of access in England and Wales to cystic fibrosis drugs from Vertex Pharmaceuticals Inc. (NASDAQ:VRTX). NICE suspended its review after the...
23:21 , Jul 13, 2018 |  BioCentury  |  Finance

Pause for politics

The near record-setting pace of 1H18 capital markets activity isn’t likely to be replicated this half, but that won’t be because of changes to sector fundamentals. Instead, it’s likely the consequence of macroeconomic and geopolitical...
21:40 , Jul 10, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Sarcoma Cell culture and mouse studies suggest combining Mekinist trametinib with IGF1R inhibitors could help treat PAX3-PAX7 fusion-negative rhabdomyosarcoma. Screening of a panel of 1,912 approved or tool compound small molecule inhibitors in a viability...
00:25 , Jun 16, 2018 |  BioCentury  |  Product Development

NSCLC disrupted

This year’s ASCO made clear that PD-1 inhibitors have supplanted chemotherapy as standard of care in first-line metastatic NSCLC. The unanticipated consequence is the knock-on effects for companies with studies under way in both first-...
16:20 , Jun 15, 2018 |  BC Week In Review  |  Company News

Zejula included on CDF

The U.K.'s NICE issued a final appraisal determination (FAD) recommending the use of Zejula niraparib from Tesaro Inc. (NASDAQ:TSRO) within the country's Cancer Drugs Fund (CDF) to treat relapsed, platinum-sensitive high-grade serous epithelial ovarian, fallopian...
15:30 , Jun 8, 2018 |  BC Week In Review  |  Company News

DRC approves compassionate use of investigational Ebola treatments

A Democratic Republic of the Congo ethics committee approved the use of five investigational Ebola therapies under compassionate use and expanded access. The World Health Organization said four of the five approved products are in the...
23:43 , May 31, 2018 |  BC Extra  |  Company News

Regeneron sends experimental Ebola therapy to Congo

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) said it began shipping its investigational Ebola antibody cocktail REGN-EB3 (REGN3470-3471-3479) to the Democratic Republic of the Congo (DRC). REGN-EB3 was one of several experimental therapies considered for the treatment of Ebola...
22:18 , May 31, 2018 |  BC Innovations  |  Translation in Brief

Sourcing neural precursor cells

UCSD team developed iPS cell-derived transplants for spinal cord injury that require minimal immunosuppression. Researchers from the University of California San Diego have demonstrated that iPS cell-derived transplants could be used to treat spinal cord...
01:18 , May 12, 2018 |  BioCentury  |  Finance

HKEX opportunity knocking

The rapid growth of biotech in the greater China region is something Jefferies does not intend to miss. With the opening of a new biotech chapter on the Hong Kong Exchanges and Clearing Ltd. on April...